Systemic Lupus Erythematosus (SLE): Pathogenesis, Classification, and Management

Systemic Lupus Erythematosus (SLE) is a chronic, multisystem autoimmune disease characterized by loss of self-tolerance, autoantibody production (especially anti-nuclear antibodies), immune complex deposition, and inflammation affecting virtually any organ.

Epidemiology

  • Female:Male = 9:1 (peak 15–45 years)
  • Higher prevalence and severity in Black, Hispanic, Asian populations
  • Genetic (HLA-DR2/DR3, IRF5, STAT4) + environmental triggers (UV, EBV, silica, drugs, hormones)

2019 EULAR/ACR Classification Criteria (Score ≥10 with positive ANA ≥1:80)

DomainCriteria (Weight)
ConstitutionalFever (2)
HematologicLeukopenia (3), Thrombocytopenia (4), Autoimmune hemolysis (4)
NeuropsychiatricSeizures (5), Psychosis (6), Acute confusional state (2)
MucocutaneousNon-scarring alopecia (2), Oral ulcers (2), Subacute cutaneous lupus (4), Acute cutaneous lupus (6)
SerosalPleurisy (5), Pericarditis (6)
MusculoskeletalJoint involvement (6)
RenalProteinuria >0.5g/day (4), Renal biopsy Class II/V (8), Class III/IV (10)
ImmunologicAnti-dsDNA (6), Anti-Smith (6), Antiphospholipid Abs (2), Low complement (3), Direct Coombs (2)

Major Organ Manifestations

  • Renal (Lupus Nephritis): 40–50%; ISN/RPS classes I–VI; leading cause of morbidity/mortality
  • Neuropsychiatric (NPSLE): Seizures, stroke, psychosis, cognitive dysfunction, transverse myelitis
  • Cardiovascular: Accelerated atherosclerosis, pericarditis, Libman-Sacks endocarditis, vasculitis
  • Pulmonary: Pleuritis, shrinking lung syndrome, PAH, alveolar hemorrhage
  • Hematologic: Cytopenias, antiphospholipid syndrome (thrombosis, pregnancy loss)
  • Cutaneous: Malar rash, discoid lupus, photosensitivity, vasculitis, calcinosis

Management Principles

  • Hydroxychloroquine (HCQ): Foundation for all SLE patients (↓ flares, thrombosis, damage, mortality)
  • Glucocorticoids: Bridge for flares; taper to lowest dose; avoid long-term >7.5 mg/day
  • Immunosuppressants: Mycophenolate (renal, non-renal), Azathioprine, Methotrexate (cutaneous/articular), Cyclophosphamide (severe renal/CNS), Rituximab (refractory), Belimumab (active autoantibody+), Anifrolumab (type I IFN signature), Voclosporin (LN)
  • Antiphospholipid syndrome: Anticoagulation (warfarin INR 2–3) for thrombosis
  • Non-pharmacologic: Sun protection, smoking cessation, vaccination (inactivated), bone health, CVD risk reduction

Monitoring

  • Disease activity: SLEDAI-2K, BILAG, PGA
  • Labs q1–3 mo: CBC, Cr, urinalysis, complement (C3/C4), anti-dsDNA
  • Renal: UPCR, biopsy if active sediment
  • Damage accrual: SLICC/ACR Damage Index

SLE requires lifelong, multidisciplinary care—early aggressive treatment improves long-term outcomes.

Medical Billing - Related Articles